



Overall Survival & Tumor response rate in Metastatic Breast cancer Chemotherapy

Rajat Rana^{1*}, Aravinda Swami¹, Soumadip Das¹, K KPerumal¹, Isha Patel²

1. Doctor of Pharmacy (Pharm.D), R.M Medical College & Hospital, Annamalai University, India 608002

2. Ph.D., Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, USA

ABSTRACT

To compare Taxanes, antitumor antibiotics and platinum containing chemotherapy regimens in the management of metastatic breast cancer in terms of overall survival, objective response rate and time to progression. Cochrane breast cancer group specialized register; cochrane central register of controlled trials (central), medline, embase, cinahl and who international clinical registry platform were searched using the appropriate search strategy selection criteria. Response rates were analysed as dichotomous variables. 35 trials were included with sample size of 16272 patients with Advanced Metastatic Breast Cancer treated with either Antitumor Antibiotics or Platinum Regimens or Taxanes. The observed overall survival derived for a sample size of 2710 exposed to chemotherapy where as a comparator group of 2591 exposed other therapies. The overall risk ratio was 0.98(M-H, fixed, 95% CI; 0.95 to 1.01). Tumor Response Rate derived for a sample size of 3037 exposed to chemotherapy in comparison to the comparator group of 2951 exposed to other therapies. This study confirms several benefits of chemotherapy especially taxanes, antitumor antibiotics and platinum regimen in metastatic breast cancer, but the selection of drug therapy must be based upon the presentation of the case.

Key words: Breast Cancer, Metastasis, Overall Survival, Tumor Response Rate.

*Corresponding Author Email rajatrana91@gmail.com

Received 04 June 2014, Accepted 25 June 2014

INTRODUCTION

Breast cancer is the most common cancer occurring in women and is the primary cause of cancer death among women worldwide. 20-85% of patients depending on stage, tumor biology and treatments used will go on to develop distant metastases (disease which has spread to other parts of the body)¹. Chemotherapy is considered by many to be the appropriate first treatment option for women with multiple sites of recurrence or where visceral disease is not easily treated by local modalities.^{2,3} Chemotherapy is also considered to be useful in women whose cancer is hormone refractory, or expected to be hormone resistant.⁴ Some women with metastatic breast cancer live for many years; however, the median survival ranges from 18 to 24 months.⁵ It is generally accepted that Taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. Taxanes are unique as they affect cell structures known as microtubules (or spindle fibers). Taxanes work by stopping the microtubules from breaking down. Cancer cells then become blocked with microtubules and stop dividing.⁶ They damage the DNA template by a variety of mechanisms including intercalation into DNA and RNA, alkylation of DNA and the generation of oxygen free radicals to produce single- and double-strand DNA breaks.⁷

The aim of this review is to systematically identify and assess all of the available evidence from randomized trials that compared the effects of different chemotherapeutic regimen on treatment-related outcomes for women with metastatic breast cancer.

This study was aimed with the primary objective to identify and compare efficacy of Antitumor Antibiotics, Platinum Regimens and Taxanes chemotherapies in the treatment of advanced metastatic breast cancer in women.

MATERIALS AND METHODS

Criteria for considering studies for this review was randomized control trials that assess the overall effectiveness and response of Antitumor Antibiotics, Platinum Regimens and Taxanes in patients with advanced Metastatic Breast Cancer. The studies could be double blinded, single blinded or unblinded, single arm or double arm. Either recurrent or newly diagnosed women with definite evidence of Advanced Metastatic Breast Cancer were included. There were no restrictions on age, estrogen receptors, metastatic site of the patient included. Outcome measures were defined a priori as follows. Overall Survival (OS) time from date randomized to date of death (any cause). Tumor Response Rate (TRR) the proportion of patients with either complete or partial shrinkage of tumors. It was assessed according to modified RECIST⁶⁹ on the basis of

the independent review of patients with measurable disease at baseline. Time to Progression (TTP) Time from date randomized to date of progression, death (any cause), may be referred as progression free survival. The Cochrane Breast Cancer Group specialized register (CBCG) was searched (issue 9 of 12, September 2013) was searched with the search strategy used by the group to create the register. This register includes both published and unpublished (including ongoing) trials. A further search was carried out in the Cochrane Central Register of Controlled Trials (CENTRAL) until 2013 (issue 10 of 12, September 2013). MEDLINE (2001 to September 2013) using the advance search strategy. In addition EMBASE (1998 to August 2013), CINAHL (1982 to September 2013) and the WHO International Clinical Registry platform search portal (September 2013) using the appropriate search strategy.

The data was extracted independently by the two authors. The most complete data set that was feasible was assembled and analyzed for the primary outcomes such as overall survival and tumor response rate. When possible, the HR was extracted from the trial publication(s). If not reported it was obtained indirectly through the methods described by Parmar *et al* using either other available summary statistics or from the data extracted from published Kaplan-Meier curves.⁸ A weighted average of survival duration across studies was then calculated. The pooled HR was obtained by combining the observed (O) minus the expected (E) number of events and the variance for each trial using the fixed effect model.⁹

Tumor response rate (TRR) was analyzed as dichotomous variables and were obtained from the tables of best response presented for each trial and pooled relative risk was derived. Randomized response as reported by the trial list was used for statistical analysis. To allow for immature follow-up the numbers at risk were adjusted based on estimated minimum and maximum follow-up times if these were not reported in any of the reports available, minimum follow-up was estimated using the estimated time taken to complete treatment, and maximum follow-up was estimated using the last event reported in the relevant time to event curve.

The statistical heterogeneity was assessed using I^2 test where a value greater than 50% indicated substantial heterogeneity.¹⁰ A fixed effect model was utilized for generating data provided no significant heterogeneity was present. The random effect model was employed in case of significant heterogeneity. Aggregate data methods^{8,11} were employed for time to event outcomes in the first instance and results were presented as Hazard ratios with 95% CI. Evidence of heterogeneity between trials were identified for tumor response rates and adverse events. We performed sensitivity analysis on the basis of methodological quality and to test for heterogeneity of the results. All analysis were based on intention to treat (ITT) principle as far as

was possible, that is comparing all patients allotted to one treatment versus all those allocated to other irrespective of compliance. Thus the results may slightly underestimate any treatment effects. For statistical test a P value of less than 0.05 was considered to denote statistical significance.

RESULTS AND DISCUSSION

35 Randomized control studies conducted on 16272 patients with Advanced Metastatic Breast Cancer treated with Antitumor Antibiotics or Platinum Regimens or Taxanes were included. The study were classified based upon primary outcomes namely Overall Survival (OS), Tumor Response Rate (TRR).




Figure 1 Forest plot of comparison of Overall Survival

In **Overall Survival** the primary analysis of overall effect as derived for a sample size of 2710 exposed to chemotherapy where as a comparator group of 2591 exposed other therapies. The overall risk ratio was 0.98(M-H, fixed,95% CI;0.95 to 1.01)Sufficient data was available from 22 randomized clinical trials with 5301 randomly assigned participants.10 Randomized study were conducted where study group treated with Anti-tumor antibiotics showed 861 events to the total sample size of 1140 whereas 874 events were recorded for a sample size 1146 treated with other therapies. The Peto odds ratio was estimated as 0.96(Peto, fixed, 95% CI; 0.79 to 1.16). The pooled Peto odds ratio was not statistically significant to document superiority of chemotherapy over other therapy. Four trials with 904 randomly assigned patients treated with Platinum regimen reported peto odds ratio 0.89(peto, fixed, 95% CI; 0.67 to 1.19). The data indicated high overall survival for the study group with chemo therapy compared to the group treated with other therapies.8 randomized clinical trials with Taxanes chemotherapy with sample size of 2111 reported peto odds ratio 0.91(peto, fixed, 95% CI; 0.75 to 1.10) which statistically favors the high overall survival with Taxanes over the comparator group. On an overall peto odds ratios was estimated 0.92 (peto, fixed,95% CI; 0.82 to 1.05) for Antitumor Antibiotics, Platinum Regimens and Taxanes. This overall effect statistically favors high overall survival when treated

with chemo therapy over the other therapies. The heterogeneity was assed as $\chi^2=0.26$. The test for overall effect was 1.24 (P=0.21)

Tumor Response Rate (TRR) had overall effect of primary analysis as derived for a sample size of 3037 exposed to chemotherapy in comparison to the comparator group of 2951 exposed to other therapies from 25 trials. The overall risk ratio was 1.15(M-H, fixed, 95% CI; 1.08 to 1.22).6 trials with a sample size of 2450 were available to enable estimation of tumor response rate for anti-tumor Regimens over other therapy to be calculated. 603 patients showed outcome out of 1273 patients in terms of increased tumor response rate, however 503 patients were treated with other therapy showed response in 1177 patients. The pooled estimation of tumor response rate significantly favor other therapy over antitumor antibiotics measured by odd ratio 1.21 (MH Fixed, 95% CI, 1.03 to 1.41).A significant difference in favor of other therapy regimens over platinum regimen detected for 1520 randomized patients in 8 clinical trials. 358 patients showed event when 687 were treated with platinum regimen with comparator group of 388 patients showing events in 833 patients. The statistical significance measured as odds ratio 1.25 (MH Fixed, 95% CI, 1.02 to 1.53).7 trials with a sample size of 2018 were included to estimate tumor response rate with treatment with Taxanes. When 1077 patients were treated with Taxanes, 443 patients showed response in terms of tumor response whereas in treatment with other regimen 296 showed events out of 941 patients. The data statistically favors treatment with other therapies over Taxanes measured as odds ratio 1.52 (MH Fixed, 95% CI, 1.27 to 1.83).Estimated pooled risk ratio for overall Tumor Response Rate was1.15 (MH Fixed, 95% CI, 1.08 to1.22) for Antitumor Antibiotics, Platinum Regimens and Taxanes. The forest plot graph significantly favors chemotherapy over other therapy. The test for significant heterogeneity was assed as $\chi^2=26.12$ and sensitivity analysis I^2 was estimated 92% the test for overall effect was 2.73 (P=0.006)




Figure 2 Forest plot of comparison of Tumor Response Rate

Presently there are more and more sophisticated cytotoxic chemotherapy available in the treatment of advance metastatic breast cancer. In incurable metastatic breast cancer the goal of the treatment is to increase overall survival, quality of life and safety profile of the chemotherapy. There is also an accepted wisdom that human with visceral metastatic tend to response better to chemotherapy. This review has combined wide data from wide variety of randomized clinical trials conducted over past 20 years. The overall heterogeneity across the trials was dubious. This reduced the power of certain analysis principally of overall survival and tumor response rate. However, the modest level of evidence recommends the beneficial outcome of chemotherapy in women with metastatic breast cancer.

The positive effects of chemotherapy were demonstrated by this review in terms of significantly high overall survival and time to progression compare to other therapies. In terms of overall survival Taxanes illustrated superiority over the Platinum and antitumor antibiotic with statistically significant increased Odds ratio. Antitumor antibiotic exhibited statistical advantage along with Taxanes over platinum regimen In terms of time to progression. The pooled estimate of objective tumor response rate in majority of included trials indicated favor advantage for other therapy over established chemotherapy. Large number of trials reported significant partial response rate and complete response rate assessed by RECIST (response evaluation criteria in solid tumor). Few subjects were observed with stable diseases and very few with progressive diseases.

Table 1 Overall Outcomes

Outcome	Studies	Participants	Statistical Method	Effect Estimate
Overall Outcomes of Chemotherapy	35	16272	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [1.01, 1.05]
Overall Survival	22	5301	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.92 [0.82 1.05]
Tumour Response Rate	25	5988	Odds Ratio (M-H, Fixed, 95% CI)	1.31 [1.18 1.45]

Table 2 Included Study Characteristics

First Author	Year	AGE		First Author	Year	AGE	
		Median Age (MA)	Age Range (AR)			Median Age (MA)	Age Range (AR)
TAXANES				TOG ^[46]	-----	-----	18-70
304 Study Group ^[12-17]	TXT Group ^[47-49]	-----	55.3	TXT Group ^[47-49]	-----	55.3	27-79,
306 Study Group ^[18,19]	-----	53	-----	PLATINUM REGIMEN			
ANZ TITG ^[20-24]	-----	54	32-80	Berruti A ^[50]	2002	57/59	-----
Bontenbal ^[25]	-----	53	-----	Berruti B ^[51]	2002	58	-----
Dieras ^[26]	-----	52/52.5	29/69	Cocconi G ^[52]	1996	57	-----
ECOG E11939(A) ^[27-30]	-----	56/58	25/79	Costanza ^[53]	1999	-----	-----
ECOG E11939(B) ^[31]	-----	56/58	25/79	Eisen ^[54]	1998	47/48	-----
EORTC 10923 ^[32,33]	-----	54/55	26/75	Fountzilas ^[55]	2002	-----	-----
EORTC 10961 ^[34,35]	-----	-----	18-70	Icli ^[56]	2002	47/49	-----
Jassem ^[36-39]	-----	50	24-74	Nielsen ^[57]	2000	52/55	-----
Nabholtz ^[40]	-----	54	-----	ANTITUMOR ANTIBIOTICS			
Sjostrom ^[41-44]	-----	50 / 51	26-69	ANZ BCTG8614 ^[58]	-----	-----	-----
Talbot ^[45]	-----	52	-----	Berruti B ^[51]	2002	58	-----
First Author	Year	AGE		AGE	Year	AGE	
		Median Age (MA)	Age Range (AR)			Median Age (MA)	Age Range (AR)
Cocconi G ^[52]	1996	57	-----	DBCG ^[60,61]	1999	58	-----
Costanza ^[53]	1999	-----	-----	ECOG EST 2173a ^[62,63]	-----	-----	61% aged 50-65, 39% <50yrs
Eisen ^[54]	1998	47/48	-----	ECOG EST 2173b ^[64]	-----	-----	-----
Fountzilas ^[55]	2002	-----	-----	Fountzilas ^[64]	2004	-----	-----
Icli ^[56]	2002	47/49	-----	Fraser ^[65]	1993	60	26-80
Nielsen ^[57]	2000	52/55	-----	Hainsworth ^[66]	1997	57	34-81
ANZ BCTG 8614 ^[58]	-----	-----	-----	Harper-Wynne ^[67]	1999	58	28-84
B122 ^[59]	-----	52	-----				

CONCLUSION

There by this review found a considerable benefit of other therapies over the chemotherapy. It is emphasized that endocrine therapy demonstrated better overall response rate in the patients with hormone receptor positive metastatic breast cancer. This study suggested the prudence introduction of chemotherapy where there are rapidly progressive diseases. The statistical heterogeneity differences can be regarded to the various differences that remain speculative. The proportion of with their hormone receptor status contributed to the differences in heterogeneity and may explain it. This review may underestimate the effect of other therapy on the survival of women but it certainly supports the included chemotherapeutic agents in this study. Conclusively, this study confirms several benefits of chemotherapy especially Taxanes, antitumor antibiotics and platinum regimen in metastatic breast cancer, but the selection of drug therapy must be based upon the presentation of the case and the various baseline factors like nodal status, the extent of metastatic and the hormonal status. The overall therapy and higher response rate should be the desired endpoint of the any therapy outlined for the patients.

REFERENCES

1. Cardoso 2002 F Cardoso, A Di Leo, C Lohrisch, C Bernard, F Ferreira, M.J. Piccart. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. *Annals of Oncology* 2002;13:197–207.
2. Hayes 1995 Hayes DF, Henderson IC, Shapiro CL. Treatment of Metastatic Breast Cancer Present and Future Prospects. *Seminars in Oncology* 1995;22(2):5–21.
3. National Cancer Institute. Cancer.gov - Breast Cancer (PDQ): Treatment Summary. <http://www.cancer.gov/cancerinfo/pdq/treatment/breast/healthprofessional/01/02/2003>.
4. Hortobagyi GN, Piccart-Gebhart MJ. Current Management of Advanced Breast Cancer.. *Seminars in Oncology* 1996;23 (Suppl 11):1–5.
5. Stockler MR, Wilcken NRC, Ghersi D, Simes RJ. The use of chemotherapy and endocrine therapy in the management of metastatic breast cancer: a series of systematic reviews. *Cancer Treatment Reviews* 2000;26(3):151–68.
6. NCI web site <http://cis.nci.nih.gov/> accessed 19th Feb, 2003
7. Perry 1997 Michael C. Perry (Ed.). *The Chemotherapy Source Book*. Vol. Second Edition, Williams and Wilkins, 1997. [ISBN 0–683–06868–7]
8. Parmar MK, Torri V, Stewart L, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, 1998 Dec 30;17(24):2815-34

9. Yusuf S, Peto R, Lewis J, Collins R, Beta blockade during and after myocardial infarction: an overview of the randomized trials, *ProgCardiovasc Dis.* 1985 Mar-Apr;27(5):335-71.
10. JPT Higgins, Measuring inconsistency in meta-analyses, *BMJ* 2003; 327:557
11. Williamson, G. R. and Prosser, S. (2002), Action research: politics, ethics and participation. *Journal of Advanced Nursing*, 40: 587–593. doi: 10.1046/j.1365-2648.2002.02416.
12. Nabholz JM. Docetaxel (Taxotere) vsmitomycin C +vinblastine in patients with metastatic breast cancer (MBC) who have failed an anthracycline-containing regimen. Preliminary evaluation of a randomized phase III study. *Proceedings of American Society of Clincial Oncology YR:1997.* 1997; Vol. 16:148a.
13. Nabholz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. *SeminOncol1998;25(6 Suppl 13):4–9.*
14. Nabholz JM, Senn HJ etal.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. *J ClinOncol1999;17(5):1413–1424.*
15. Nabholz JM, Thuerlimann B, Taxotere (T) improves survival over mitomycin C vinblastine (mv) in patients (pts) with metastatic breast cancer (mbc) who have failed an anthracycline (ant) containing regimen: final results of a phase III randomized trial.. *Proceedings of the American Society of Clinical Oncology.* 1998; Vol. 17:101a no. 390.
16. Nabholz JM, Thuerlimann B, Docetaxelvsmitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. *Oncology (Huntington)* 1997;11(8 Suppl 8):32–37.
17. Nabholz JM, Thuerlimann B, etal.Taxoterevsmitomycin c-vinblastine in patients with metastatic breast cancer who have failed an anthracycline containing regimen. *Breast Cancer Research & Treatment YR:1997.* 1997; Vol. 46, issue 1:93.
18. Nabholz J-M, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as firstline chemotherapy for metastatic breast cancer: results of a radnomized, multicenter, phase III trial. *Journal of Clinical Oncology* 2003;21(6):968–975.
19. Nabholz JM, Falkson G, A Phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. *Proceedings of the American Society of Clinical Oncology.* 1999; Vol. 18:127a (Abstract

20. Australia and New Zealand Taxol Investigators Trials Group. Taxol versus CMFP combination therapy in advanced untreated patients with breast cancer (protocol). Trial protocol 1995.
21. Bishop JF, Dewar J, Tattersall MH, Smith J, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Toner G, Stephenson J. A randomized phase III study of Taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer Meeting abstract). Proceedings of American Society of Clinical Oncology. 1996; Vol. 15: ABS. A107.
22. Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/ prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. *SeminOncol*1997; 24(5 Suppl 17):S17–5-S17-9.
23. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. *J ClinOncol*1999;17(8):2355–2364.
24. Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackl S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J. Paclitaxel as first-line treatment for metastatic breast cancer. *Oncology (Huntington)* 1997;11(4 SUPPL. 3):19–23.
25. Bontenbal M, Braun JJ, Creemers GJ, de Boer AC, Janssen JTP, Leys MBL, Schothorst KLC, Schmitz PIM, Bokma JJ, Seynaeve C. Phase III study comparing AT to FAC as firstline chemotherapy in patients with metastatic breast cancer. *European Journal of Cancer Supplements*. September 2003; Vol. 1:S201.
26. Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, Mignot, L, Chazard M, Garet F, Onetto N, et al.Mignot L, et al.Phase II randomised study of paclitaxel versus mitomycin in advanced breast cancer. *SeminOncol* 1995;22(4 Suppl 8):33–39.
27. Sledge GW. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. *SeminOncol* 1995;22(5 Supp 12):123–129.
28. Sledge GW, Jr, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proceedings of the American Society of Clinical Oncology YR:1997. 1997; Vol. 16.

29. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III Trial of Doxorubicin, Paclitaxel and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). *Journal of Clinical Oncology* 2003;21(4):588–592.
30. Sledge GWJ, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill Stevens W. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. *SeminOncol* 1995; 22:105–108.
31. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III Trial of Doxorubicin, Paclitaxel and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). *Journal of Clinical Oncology* 2003;21(4):588–592.
32. Awada A, Paridaens R, Bruning P, et al. Doxorubicin or taxol as first-line chemotherapy for metastatic breast cancer: Results of an EORTC-IDBBC/ECSG randomised trial with Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. *J ClinOncol* 2000;18(4):724–733.
33. Piccart-Gebhart MJ, Bruning P, Gamucci T, Klijn J, Roy JA, Awada A, Kusenda Z, Van Vreckem A, Paridaens R. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. *SeminOncol* 1996;23(5 Suppl 11):11–15.
34. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeat P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and Paclitaxel versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: EORTC 10961. *Journal of Clinical Oncology* 2002;20(14):3114–3121.
35. Piccart-Gebhart MJ. Phase III randomised study of first-line chemotherapy with doxorubicin/paclitaxel vs doxorubicin/cyclophosphamide in metastatic breast cancer. *Physician Data Query (NCI web site)* 1998.
36. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrcic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with

- metastatic breast cancer: final results of a randomized phase III multicenter trial. *J Clin Oncol* 2001;19(6):1707–1715.
37. Pluzanska, A, Pienkowski, T, Jelic, S, Mrcic-Krmpotic, Z, Gorbunova, V, Garin, A, Jassem, J, Nagykalnai, T, Pawlicki, M, Filipczyk-Cisarz, E, Weil, C, Statuch. C. Phase III multicenter trial comparing Taxol®/Doxorubicin (AT) vs 5-fluorouracil/Doxorubicin and Cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer. *Breast Cancer Research & Treatment. San Antonio Breast Cancer Symposium, 1999; Vol. 57: Abstract 21.*
38. Pluzanska, A, Jassem J, Jelic, S, Gorbunova, V, Mrcic- Krmpotic, Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Statuch C. Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin
39. Pluzanska, A, Jassem J, Jelic, S, Gorbunova, V, Mrcic- Krmpotic, Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Statuch C. Randomized open-label phase III multicenter trial comparing TAXOL/doxorubicin (AT) versus 5- fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer. *European Journal of Cancer* 1999;35(Suppl 4):S314, Abstract 1260.
40. Nabholz JA, Paterson A, Dirix L, Dewar J, Chap L, Martin M, Chan S, Tang S, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Borg-Oliver O, Riva A, Murawsky M, Azli N, Efremidis A. A phase III randomized trial comparing Docetaxel (T), Doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (Pts) with metastatic breast cancer (MBC). *Proceeding of the American Society of Clinical Oncology* YR:12-5-2001; Vol. 20, issue Part 1:22a.
41. Hakamies-Blomqvist L, Luoma M, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lonn S, Bergh J, Malmstrom P, Blomqvist C. Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5- fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. *Eur J Cancer* 2000;36(11): 1411–1417.
42. Luoma ML. Hakamies-Blomqvist L. Sjostrom J. Pluzanska A. Ottosson S. Mouridsen H. Bengtsson NO. Bergh J. Malmstrom P. Valvere V. Tennvall L. Blomqvist C. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. *Eur J Cancer* 2003;39(10):1370–6. [MEDLINE: 12826039 12826039]

43. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5- fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. *Eur J Cancer* 1999;35(8):1194–1201.
44. Sjostrom J, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson N-O, Ostenstad B, Mjaaland I, Malmstrom P, Bergh J, Wist E, Valvere V, Blomqvist C. Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandanavian breast cancer group.. *Proceedings of the American Society of Clinical Oncology*. 1998; Vol. 17:111a no. 427
45. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, AlboConejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger H-U, Laws S, OsterwalderB. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/ advanced breast cancer pretreated with anthracyclines. *British Journal of Cancer* 2002;86:1367–1372.
46. Icli F, Akbulut H, Uner A, Bulent Y, Altinbas M, Baltali E, Komucu S, Erkisi M, Demirkazik A, Senler FS. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. *Annals of Oncology* 2002; 13:47.
47. Bonneterre, J, Roche, H, Monnier, A, Fargeot, P, Namer, M, Guastella, J. P, Rios, M, Serin, D, Culine, S, Tubiana, M, Eymard, J. C, Assadourian. S. Docetaxel (D) versus 5 fluorouracil- vinorelbine (FUN) in patients (PTS) with metastatic breast cancer (MBC) as second line chemotherapy: a phase III study.. *Breast Cancer Research & Treatment*. 1998; Vol. 50:Abstract 223.
48. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian, S. Docetaxel vs 5- fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. *British Journal of Cancer* 2002;87(11):1210–1215. [MEDLINE: 22325575]
49. Monnier A, Bonneterre J, Roche H, Fargeot P, Namer M, GJ. Phase III study: Taxotere r (TXT) versus 5-fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results). *Ann Oncol* 1998; 9:12.

50. Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L, Epirubicin-Lonidamine Group. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. *J ClinOncol* 15–10–2002;20(20):4150–4159.
51. Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L, Epirubicin-Lonidamine Group. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. *J ClinOncol* 15–10–2002;20(20):4150–4159.
52. Cocconi G, Bella M, Bartolucci R, Basurto C, Colozza M, Indelli M. Continuous CMF compared to a short chemotherapy using cisplatin-containing combinations in metastatic breast carcinoma. A prospective randomized study. *Ann Oncol* 1996;7(Suppl 5):22.
53. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E3, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642. *J ClinOncol* 1999;17(5): 1397–1406.
54. Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT, Walsh G, Ashley S. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. *J ClinOncol* 1998;16(4):1350–1357.
55. Fountzilias G, Kalofonos HP, Bafaloukos D, Kosmidis P, Gogas H, Skarlos DV, Economopoulos T, Pavlidis N, Aravantinos G, Dimopoulos MA. Paclitaxel and epirubicin versus paclitaxel and carboplatin, as first line chemotherapy, in patients with advanced breast cancer (ABC). A phase III study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* YR:2002. 13 Vol. 13:46.
56. Icli F, Akbulut H, Uner A, Bulent Y, Altinbas M, Baltali E, Komurcu S, Erkisi M, Demirkazik A, Cay Senler F. Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: A phase III randomized study, Turkish Oncology Group. *Ann Oncol* YR:2002. 13 Vol. 13:47.

57. Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. *Cancer Chemotherapy & Pharmacology* 2000;46(6):459–466.
58. Simes RJ. Mitozantronevs CMFP in advanced breast cancer: A quality of life study. *Proceedings of ASCO* 1994;2001.
59. Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, et al. A randomised comparative trial of adriamycin versus methotrexate in combination drug therapy. *Cancer* 1978;41:1649–57. Falkson G, Tormey DC, Carey P, Witte R, Falkson HC. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. *Eur J Cancer* 1991;27(8):973–7.
60. Andersson M, Madsen EL, Overgaard M, Dombernowsky P, Mouridsen HT. CAF vs CMF with tamoxifen in postmenopausal patients with advanced breast cancer – A randomized study with more than 10 years follow-up from the Danish breast cancer cooperative group. *European Journal of Cancer*. 33 1997; Vol. 33, issue Suppl 8:S146.
61. Andersson M, Madsen EL, Overgaard M, Rose C, Dombernowsky P, Mouridsen HT. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer -a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. *Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer* 1999;35(1):39–46.
62. Tormey DC, Gelman R, Band PR, Sears M, Bauer M, Arseneau JC, Falkson G, Falkson G. A prospective evaluation of chemohormonal therapy remission maintenance in Antitumour antibiotic containing regimens for metastatic breast cancer (Review) 15 Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. advanced breast cancer. *Breast Cancer Research & Treatment* 1981;1(2):111–9.
63. Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, et al. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. *Cancer* 1982;50(7):1235–44.
64. Fountzilas G, Kalofonos H.P, Dafni U, Papadimitrou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos L.A, Economopoulos T, Pectasides D, Maniadas N, Sifaka V, Briasoulis E, Christodoulou C, Tasavaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos M.A. Paclitaxel
65. Anonymous. Combination versus mild single agent chemotherapy for advanced breast cancer. *UKCCCR Register of Cancer Trials* 2002. Fraser SC, Dobbs HJ, Ebbs SR,

- Fallowfield LJ, Bates T, Baum M. Combination or mild single agent chemotherapy for advanced breast cancer? CMF v sepirubicin measuring quality of life. *British Journal of Cancer* 1993;67(2):402–6.
- Fraser SC, Ramirez AJ, Ebbs SR, Fallowfield LJ, Dobbs HJ, Richards, MA, et al. A daily diary for quality of life measurement in advanced breast cancer trials. *British Journal of Cancer* 1993;67(2):341–6.
66. Hainsworth, J.D. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomised comparison to cyclophosphamide, methotrexate, and 5- fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel. *European Journal of Cancer Care* 1997;6(Supplement 1):4–9.
- Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5- fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma. A randomized phase II trial. *Cancer* 1997;79(4):740–8.
67. Harper-Wynne C, English J, Meyer L, Bower M, Archer C, Sinnott HD, et al. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. *British Journal of Cancer* 1999;81(2):316–22.
68. Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D, HEPI. Dose-intensive epirubicinbased chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. *Journal of Clinical Oncology* 2001;19(4):943–53.
69. Eisenhauer, E. A., et al. "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)." *Eur J Cancer* 2009;45(2): 228-247.



AJPHR is
Peer-reviewed
monthly
Rapid publication
Submit your next manuscript at
editor@ajphr.com / editor.ajphr@gmail.com